

# **ACIP Hepatitis Work Group**

## **Mark Sawyer, MD – Chair**

# **Introduction**

June 20, 2012

National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention

Division of Viral Hepatitis



## **Term of Reference**

- ❑ Ensure hepatitis B protection for healthcare personnel (HCP), including trainees, who received Hepatitis B (HepB) vaccination in the past without post-vaccination serologic testing<sup>1</sup>**
- ❑ 10 year time frame, recommendations under discussion considered interim**

<sup>1</sup>Or who no longer have a record of post-vaccination serologic test result

# Synopsis of Issue

- ❑ **Post-vaccination serologic testing (antibody to hepatitis B surface antigen [anti-HBs]) recommended 1-2 months after HepB vaccine series for HCP at high risk for exposure to blood and body fluids<sup>1</sup>**
- ❑ **Increasing proportion of HCP entering training and workforce have received HepB vaccine series in remote past as part of routine infant (or catch-up) vaccination**
  - Post-vaccination serologic testing not recommended after routine infant (or catch-up) HepB vaccination<sup>2</sup>

<sup>1</sup>MMWR 2011

<sup>2</sup>MMWR 2005

# Work Group Discussed 5 Approaches to Evaluate for Protection

---

## Post-exposure evaluation

---

1. All sources (HBV-negative, positive, or unknown)
  - b. HBV-positive or unknown sources
- 

## Pre-exposure evaluation

---

2. Anti-HBs testing; HepB dose if necessary
  3. HepB dose and anti-HBs testing
- 

## Hybrid evaluation

---

- a. Pre-exposure HepB dose; post-exposure, all sources

❑ Examined separately for trainees and non-trainees

# **Work Group Activities**

- ❑ 10 Work Group teleconferences**
- ❑ ACIP presentations February 2012**
- ❑ HICPAC presentation June 2012**
- ❑ ACIP presentations today**
  - Overview of issues
  - Model inputs for cost-effectiveness analyses
  - Results of cost-effectiveness analyses
  - Recommendations under discussion

# Members of ACIP Hepatitis Work Group

- ❑ Mark Sawyer, ACIP, Chair
- ❑ Douglas Campos Outcalt, ACIP
- ❑ Kristen Ehresmann, ACIP
- ❑ Jonathan Temte, ACIP
- ❑ Alexis Elward, HICPAC Liaison
- ❑ Stephen Feinstone, FDA
- ❑ Kathleen Harriman, CDPH
- ❑ Samuel Katz, Former ACIP Chair
- ❑ Harry Keyserling, SHEA Liaison
- ❑ Thomas Koinis, AAFP
- ❑ Myron Levin, Former ACIP Chair
- ❑ Brian McMahon, ANTHC
- ❑ Amy Middleman, SAHM Liaison
- ❑ David Nace, AMDA
- ❑ Poki Namkung, NACCHO
- ❑ Georges Peter, Brown U
- ❑ Brenna Simons, ANTHC
- ❑ James Turner, ACHA Liaison
- ❑ David Weber, SHEA
- ❑ Geoff Beckett, CDC/DVH
- ❑ Kathy Byrd, CDC/DVH
- ❑ Scott Holmberg, CDC/DVH
- ❑ Erin Kennedy, CDC/ISD
- ❑ David Kuhar, CDC/DHQP
- ❑ Trudy Murphy, CDC/DVH
- ❑ Marie de Perio, NIOSH
- ❑ Sarah Schillie, CDC/DVH
- ❑ Philip Spradling, CDC/DVH
- ❑ Eyasu Teshale, CDC/DVH
- ❑ Cindy Weinbaum, CDC/DHQP
- ❑ Fujie Xu, CDC/DVH